{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:26:41Z","timestamp":1778902001277,"version":"3.51.4"},"reference-count":37,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,9,15]],"date-time":"2004-09-15T00:00:00Z","timestamp":1095206400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:p><jats:bold>Objectives\n\t\t\t\t\t<\/jats:bold> To describe the management of primary HIV infection (PHI), focusing on changes in the design of therapies and time to initiation of antiretroviral treatment, the clinical outcome, and the immuno\u2010virological response over time to highly active antiretroviral therapy (HAART) and its tolerance.<\/jats:p><jats:p><jats:bold>Design and methods\n\t\t\t\t\t<\/jats:bold> In the French PRIMO multicentre cohort, 291 patients presenting with PHI were enrolled between 1996 and 2001. Data were analysed to describe treatment prescription habits over a period of 5 years, and response to and tolerance of treatment.<\/jats:p><jats:p><jats:bold>Results\n\t\t\t\t\t<\/jats:bold> The proportion of patients who initiated treatment during PHI decreased from 92% in 1996 to 56% in 2001. At 6 months, whatever the initiated treatment, 74% of treated patients achieved a plasma viral load&lt;400 HIV\u20101 RNA copies\/mL and 53% achieved a viral load of&lt;50 copies\/mL. Prescription of protease inhibitor (PI)\u2010sparing regimens has become more frequent since 1999. Despite a similar virological response, patients in the PI\u2010containing group tended to experience a greater 1\u2010year increase in CD4 cell count than those in the non\u2010nucleoside reverse transcriptase (NNRTI)\u2010containing group (218 cells\/\u03bcL versus 157 cells\/\u03bcL, respectively). An adverse event was recorded in 51% of treated patients. The most frequent events were gastrointestinal disorders (71%), lipodystrophy (27%) and mood disorders (19%). The main reason for modifying or stopping therapy was the occurrence of an adverse event.<\/jats:p><jats:p><jats:bold>Conclusions\n\t\t\t\t\t<\/jats:bold> Limitations of therapy and poor tolerance to antiretroviral regimens have changed physician attitudes in PHI. This suggests the need for evaluation of better\u2010tolerated regimens and new therapeutic strategies.<\/jats:p>","DOI":"10.1111\/j.1468-1293.2004.00231.x","type":"journal-article","created":{"date-parts":[[2004,9,15]],"date-time":"2004-09-15T15:48:04Z","timestamp":1095263284000},"page":"326-333","source":"Crossref","is-referenced-by-count":24,"title":["Recent changes in the management of primary HIV\u20101 infection: results from the French PRIMO cohort"],"prefix":"10.1111","volume":"5","author":[{"given":"V","family":"Schiffer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Deveau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Iraqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Nguyen\u2010Wartel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u2010L","family":"Chaix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u2010F","family":"Delfraissy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Rouzioux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Venet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Goujard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the French PRIMO Cohort Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,9,15]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710303371803"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/35035103"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.7.3382"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/315202"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.5.1743.005k14_1743_1751"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/320189"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/314868"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.193.2.169"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-5_Part_2-200209031-00001"},{"key":"e_1_2_6_11_2","first-page":"222","article-title":"Antiretroviral treatment for adult HIV infection in 2002","volume":"288","author":"Yeni PG","year":"2002","journal-title":"updated recommendations of the International AIDS Society\u2014USA Panel"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199508173330702"},{"key":"e_1_2_6_13_2","first-page":"1342","article-title":"Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV\u20101 infection","volume":"180","author":"Hoen B","year":"1999","journal-title":"results of the ANRS 053 trial"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/315753"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/320189"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200005050-00001"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/368333"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/8394"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-1-200007040-00004"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb03914.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101260-00024"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905273402114"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/35035103"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912163412501"},{"key":"e_1_2_6_26_2","first-page":"53","article-title":"Virological suppression at 6 months is related to choice of initial regimen in antiretroviral\u2010naive patients","volume":"16","author":"Matthews GV","year":"2002","journal-title":"a cohort study"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/314890"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200201040-00004"},{"key":"e_1_2_6_29_2","first-page":"793","article-title":"Genotypic drug resistance during HIV\u20101 primary infection in France (1996\u20131999)","volume":"16","author":"Harzic M","year":"2002","journal-title":"frequency and response to treatment"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200312050-00011"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/088922200308972"},{"key":"e_1_2_6_32_2","first-page":"1155","article-title":"Abacavir\u2010lamivudine\u2010zidovudine vs indinavir\u2010lamivudine\u2010zidovudine in antiretroviral\u2010naive HIV\u2010infected adults","volume":"285","author":"Staszewski S","year":"2001","journal-title":"a randomized equivalence trial"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200201250-00014"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200106150-00008"},{"key":"e_1_2_6_35_2","first-page":"1322","article-title":"Prevalence of adverse events associated with potent antiretroviral treatment","volume":"358","author":"Fellay J","year":"2001","journal-title":"Swiss HIV Cohort Study"},{"key":"e_1_2_6_36_2","first-page":"290","article-title":"A propos d'un \u00e9tat m\u00e9lancolique atypique sous Sustiva\u00ae (Efavirenz) [Apropos of atypical melancholia with Sustiva (efavirenz)]","volume":"27","author":"Lang JP","year":"2001","journal-title":"Encephale"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.5.725"},{"key":"e_1_2_6_38_2","first-page":"2441","article-title":"Failure to maintain long\u2010term adherence to highly active antiretroviral therapy","volume":"15","author":"Duran S","year":"2001","journal-title":"the role of lipodystrophy"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2004.00231.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2004.00231.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T11:56:54Z","timestamp":1697371014000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2004.00231.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1111\/j.1468-1293.2004.00231.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2004.00231.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}